[HTML][HTML] Role of prostanoids, nitric oxide and endothelin pathways in pulmonary hypertension due to COPD
Pulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) is
classified as Group 3 PH, with no current proven targeted therapies. Studies suggest that …
classified as Group 3 PH, with no current proven targeted therapies. Studies suggest that …
Analyzing the molecular mechanism of xuefuzhuyu decoction in the treatment of pulmonary hypertension with network pharmacology and bioinformatics and verifying …
X Yu, W Qin, H Cai, C Ren, S Huang, X Lin… - Computers in Biology …, 2024 - Elsevier
Background XueFuZhuYu (XFZY), a typical Chinese herbal formula, has remarkable clinical
effects for treating Pulmonary Hypertension (PH) with unclear mechanisms. Our research …
effects for treating Pulmonary Hypertension (PH) with unclear mechanisms. Our research …
Management of pulmonary hypertension associated with chronic lung disease
I Blanco, F Hernández-González… - … in Respiratory and …, 2023 - thieme-connect.com
Pulmonary hypertension (PH) is a common complication of chronic lung diseases,
particularly in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases …
particularly in chronic obstructive pulmonary disease (COPD) and interstitial lung diseases …
[HTML][HTML] Efficacy of sildenafil in patients with severe COVID-19 and pulmonary arterial hypertension
OV Oliynyk, M Rorat, OV Strepetova, SO Dubrov… - Viruses, 2023 - mdpi.com
Pulmonary arterial hypertension (PAH) is common in severe coronavirus disease 2019
(COVID-19) and worsens the prognosis. Sildenafil, a phosphodiesterase-5 inhibitor, is …
(COVID-19) and worsens the prognosis. Sildenafil, a phosphodiesterase-5 inhibitor, is …
Burden of pulmonary hypertension due to chronic obstructive pulmonary disease: Analysis of exacerbations and healthcare resource utilization in the United States
JR Klinger, B Wu, K Morland, P Classi, R Fiano… - Respiratory …, 2023 - Elsevier
Background The burden of pulmonary hypertension (PH) among patients with chronic
obstructive pulmonary disease (COPD) is not well understood. The present retrospective …
obstructive pulmonary disease (COPD) is not well understood. The present retrospective …
[HTML][HTML] Effects of pulmonary rehabilitation on systemic inflammation in chronic obstructive pulmonary disease: a meta-analysis
XA Yue, Y Sheng, J Li - American Journal of Clinical and …, 2024 - ncbi.nlm.nih.gov
Chronic obstructive pulmonary disease (COPD) is marked by both lung-related and systemic
symptoms, notably chronic inflammation. Despite pulmonary rehabilitation (PR) being a …
symptoms, notably chronic inflammation. Despite pulmonary rehabilitation (PR) being a …
[HTML][HTML] Inhibition of miR-4640-5p alleviates pulmonary hypertension in chronic obstructive pulmonary disease patients by regulating nitric oxide synthase 1
Z Yang, P Li, Q Yuan, X Wang, HH Ma, B Zhuan - Respiratory Research, 2023 - Springer
Background Pulmonary hypertension (PH) is a devastating disease characterized by
vasoconstriction and vascular remodeling, leading to right ventricular failure and death. PH …
vasoconstriction and vascular remodeling, leading to right ventricular failure and death. PH …
Pulmonary hypertension in chronic obstructive pulmonary disease: current understanding, knowledge gaps and future directions
WT Atchley, TK Kakkera - Current Opinion in Pulmonary Medicine, 2024 - journals.lww.com
As the PAH population-base ages and comorbid diseases become more frequently
diagnosed in PAH patients, the need to clearly delineate subpopulations for clinical …
diagnosed in PAH patients, the need to clearly delineate subpopulations for clinical …
[HTML][HTML] The Potential Important Role of Mitochondrial Rieske Iron–Sulfur Protein as a Novel Therapeutic Target for Pulmonary Hypertension in Chronic Obstructive …
L Truong, YM Zheng, YX Wang - Biomedicines, 2022 - mdpi.com
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death
worldwide, which is often due to pulmonary hypertension (PH). The underlying molecular …
worldwide, which is often due to pulmonary hypertension (PH). The underlying molecular …
[HTML][HTML] Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease
Y Suzuki, T Nagaoka, Y Terayama, Y Nagata… - Respiratory …, 2024 - Elsevier
Background The prognosis of pulmonary hypertension (PH) associated with connective
tissue diseases related to interstitial pneumonia (CTD-IP PH) is relatively good among …
tissue diseases related to interstitial pneumonia (CTD-IP PH) is relatively good among …